Navigation Links
Promyelocytic in Medical News

Insights into Acute Promyelocytic Leukemia

The research, published in the July issue of the journal Cancer Cell, published by Cell Press , illuminates specific mechanisms involved in development of acute promyelocytic leukemia (APL) and identifies promising new avenues to develop treatments for some of its variant forms. Results from t...

Arsenic-based therapy shown to help eradicate leukemia-initiating cells

...ellular proliferation and senescence. PML is commonly associated with acute promyelocytic leukemia (APL), in which it leads to the formation of a fusion protein that...argets PML for degradation and is currently used for the treatment of acute promyelocytic leukemia. As predicted, inhibition of PML by As2O3 successfully disrupted L...

Medical research is essential to improving the economy and bettering lives

...es that the human papillomavirus vaccine, the antibiotic elimination of H. pyloriinduced peptic ulcer disease, and the all-trans-retinoic acid cure of promyelocytic leukemia are all cost-effective advances that have improved lives and lowered costs. Of course, these advances took years to achieve, and long-term ro...

Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting

...c Regulation in Hematologic Malignancy -- Poster Board No. 312-II: DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute promyelocytic Leukemia (Abstract #2122). -- Poster Board No. 402-III: Up-Regulation of miR-195 Expression Leads to Decreased Expression of Basic Fibrob...

TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA

...udes TRISENOX(R) (arsenic trioxide) Injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Arsenic Poison can Make Longer Life of Leukemia Patients

...stify including arsenic trioxide in standard first-line treatment" of acute promyelocytic leukemia (APL) a rare form of acute myeloid leukemia (AML), Powell argued. ...nic-based medicine is made by Cephalon, Inc and marketed as Trisenox. Acute promyelocytic leukemia represents about 10 percent of cases of acute myeloid leukemia, an...

Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down

... New research shows that a form of vitamin A used to treat acute promyelocytic leukemia induces changes in an unusual class of small molecules called micr...o State's James Cancer Hospital and Solove Research Institute. Acute promyelocytic leukemia occurs when cells that give rise to a form of white blood cell bec...

Arsenic Compound Effective in Treating Rare Leukemia

...enic compound, coupled with standard chemotherapy treatments, significantly increases long-term survival. Patients all had newly-diagnosed acute promyelocytic leukemia, or APL, and participated in a multi-year national phase III clinical study. Twenty eight patients from NSUH and LIJ enrolled in the clinical...

Citrinin, a fungal toxin, induces apoptosis via mitochondrial pathway

...t CTN induces apoptosis through the mitochondria-dependent pathway in human promyelocytic leukemia cells (HL-60) and the process is not directly correlated with cellular oxidative stress. For the study, human promyelocytic leukemia (HL-60) cells were chosen to identify the apoptotic process induce...
Promyelocytic in Medical Technology

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... a rituximab-containing regimen and TRISENOX(R) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory acute promyelocytic leukemia. In Europe, Cephalon markets three additional oncology products in 19 countries. About Cephalon, Inc. Founded in 1987, Cephal...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting

...s four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com. Contact I...

Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting

...s four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com. Contact I...

Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells

...ed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL). Since its inception, SWCRF has trained and supported more than 170 scientists with research grants exceeding $60 million. Based in N...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

...s four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com. Forward-loo...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

...s four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com. Gleevec(R) ...
Promyelocytic in Medical Dictionary

Nose bleeds

.... nose may break and bleed , causing ... Acquired Aplastic Anemia - nose bleeds . Acquired prothrombin deficiency - nosebleeds ... Acute promyelocytic leukemia - nose bleeds . more causes... Reviews often overlooked causes of nose bleeds (epistaxis) including vitamin K deficiencies, a...
Promyelocytic in Biological News

New insights into the regulation of PTEN tumor suppression function

...tand how this happens." Examination of the abnormal blood cells of acute promyelocytic leukemia (APL) led to the discovery that PTEN had become loosened from the ...ther tumor suppressor known as PML [whose mutation is a main cause of acute promyelocytic leukemia] was at the root of PTEN's escape from the nucleus," adds the stud...

Leukemia drug turns mini-molecules up, cancer genes down

... New research shows that a form of vitamin A used to treat acute promyelocytic leukemia induces changes in an unusual class of small molecules called micr...io State's James Cancer Hospital and Solove Research Institute. Acute promyelocytic leukemia occurs when cells that give rise to a form of white blood cell bec...
Promyelocytic in Biological Technology

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

... rituximab-containing regimen and TRISENOX((R)) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory acute promyelocytic leukemia. In Europe, Cephalon markets three additional oncology products in 19 countries. About Cephalon, Inc. Founded in 198...

Telik Reports Preclinical Results at AACR Annual Meeting

...and parenterally against a wide variety of human tumor types, including breast, pancreatic, prostate, and colorectal carcinomas, as well as glioma and promyelocytic leukemia. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small ...

Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research

...a novel glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1, which induces apoptosis, or programmed cell death, in human HL60 promyelocytic cells and TF-1 erythroleukemic cells. Treatment of the leukemia cells with TLK199 also resulted in an increase of the phosphorylation of eIF2alpha,...

Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain

...treatment of metastatic breast cancer; TARGRETIN(R) (bexarotene) for advanced cutaneous T-cell lymphoma; and TRISENOX for relapsed or refractory acute promyelocytic leukemia. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-loo...

Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia

...udes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid l...

FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia

...tfolio in the United States includes TRISENOX, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL), and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute mye...

Automated RNA Amplification for Arrays

... yield (Panel A) and purity (Panel B) of eight replicates of 2 g promyelocytic Leukemia, Human Liver, and Universal Human Reference total RNA s...plicates of three different total RNA samples (Ambion #7836 HL60 promyelocytic Leukemia, Ambion #7960 Human Liver, Stratagene #740000 Universal...

Uses and Applications of FuGENE 6 Transfection Reagent

...ery of vectors for shRNA experiments (Application Note available soon). Removal of promyelocytic leukemia protein (PML) in NIH 3T3 cells by PML-specific shRNA (P. Paddison & G. Hannon, unpublished results). The...
Promyelocytic in Biological Products

Anisomycin from Sigma-Aldrich

Description:...otein synthesis. Acts by inhibiting peptidyl transferase activity in eukaryote ribosomes. Reported to induce apoptosis in a variety of cells including promyelocytic leukemia cells, Jurkat cells, ventricular myocytes, and colon adenocarcinoma cells. Initiates intracellular signals and immediate early gene induction...
Company:Sigma-Aldrich
Promyelocytic in Biological Dictionary

Topoisomerase

...nizes double-stranded DNA but only ... Original Article from The New England Journal of Medicine -- DNA Topoisomerase II in Therapy-Related Acute promyelocytic Leukemia of topoisomerase III has no effect on the accumula ... topoisomerase III RuvC double mutants that can be ... type-1 topoisomerase is...

Dicentric

...dicentric aberrations and micronuclei ... Please enter a Recipient Address and/or check the Send me a copy checkbox. ... We report a case of acute promyelocytic leukemia with dicentric chromosome resulting from translocation of chromosomes 11, 17, and 18. Dicentric Y chromosome in mixed gonadal ...
Other Tags
(Date:10/22/2014)... (PRWEB) October 22, 2014 On October ... Minds featuring skin diseases both fictional and real. ... (CEHMDF), a nonprofit organization committed to advocacy and philanthropy ... CBS will take the opportunity to impart truth and ... , There are many misconceptions about Morgellons ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is ... extension of her life’s mission. Her extensive experience in the ... of FirstLight HomeCare, make it clear that Hunter’s mission is ... my work makes a difference in the lives of others,” ... after much research, I felt ready to start on this ...
(Date:10/22/2014)... Kentucky (PRWEB) October 22, 2014 Shriners ... agreement that will change the current location of Shriners ... to South Limestone across from the University of Kentucky ... a state-of-the-art ambulatory care center, owned and operated by ... the orthopaedic needs of children and their families well ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
Other Contents